Radiotherapy for Adrenal Metastases from Hepatocellular Carcinoma: A 20-Year Bi-Institutional Experience
Current Oncology · 01.06.2026 · 33 (6) · 328
DOI: 10.3390/curroncol33060328 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Current Oncology, online erschienen am 01.06.2026. Verfasst von Jeongshim Lee und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Inha University Hospital, Inha University School of Medicine, Incheon 22332, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Adrenal Gland Neoplasms. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
To evaluate tumor response, local control (LC), survival, and toxicity after radiotherapy for adrenal metastases from hepatocellular carcinoma (HCC), we conducted a retrospective, bi-institutional study spanning two decades.
Methods
Twenty patients received radiotherapy for adrenal metastases (2005–2025). Techniques included three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, stereotactic body radiotherapy, and MR-guided radiotherapy. Tumor response was assessed using Response Evaluation Criteria in Solid Tumors version 1.1. LC, overall survival (OS), and progression-free survival (PFS) were estimated using Kaplan–Meier; the association between biologically effective dose (BED10) and local recurrence was assessed using Fisher’s exact test.
Results
The objective response rate was 55.0%, and the disease control rate was 95.0%. The 6- and 12-month adrenal LC rates were 94.4% and 87.2%; local recurrence occurred in three patients (15.0%). No local recurrence was observed at BED10 ≥ 75 Gy (0/8) versus 25.0% (3/12) at BED10 < 75 Gy. However, this difference did not reach statistical significance (p = 0.242, Fisher’s exact test) and should be interpreted as exploratory and hypothesis-generating given the limited sample size. Median OS was 13.4 months, and median PFS was 6.3 months. Systemic progression was the predominant failure pattern. No grade ≥3 radiotherapy-related toxicity was observed.
Conclusions
Radiotherapy achieved favorable LC with acceptable toxicity across a 20-year bi-institutional experience, supporting its role as an effective local treatment modality for adrenal metastases from HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Inha University Hospital, Inha University School of Medicine, Incheon 22332, Republic of Korea.
- Department of Radiation Oncology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
ORCID-Profile: Jeongshim Lee, Myungsoo Kim
Zitieren
APA
Lee, J., & Kim, M. (2026). Radiotherapy for Adrenal Metastases from Hepatocellular Carcinoma: A 20-Year Bi-Institutional Experience. Current Oncology, 33(6), 328. https://doi.org/10.3390/curroncol33060328
Vancouver
Lee J, Kim M. Radiotherapy for Adrenal Metastases from Hepatocellular Carcinoma: A 20-Year Bi-Institutional Experience. Current Oncology. 2026;33(6):328. doi:10.3390/curroncol33060328
BibTeX
@article{Lee2026,
author = {Lee, Jeongshim and Kim, Myungsoo},
title = {Radiotherapy for Adrenal Metastases from Hepatocellular Carcinoma: A 20-Year Bi-Institutional Experience},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {6},
pages = {328},
doi = {10.3390/curroncol33060328}
}
EUVIMED